Search

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

12.3 0.24

Overview

Share price change

24h

Current

Min

11.72

Max

12.4

Key metrics

By Trading Economics

Income

-8.9M

-8M

Sales

3.7M

139M

P/E

Sector Avg

121.8

57.366

Profit margin

-5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+17.65% upside

Market Stats

By TradingEconomics

Market Cap

205M

2.1B

Previous open

12.06

Previous close

12.3

News Sentiment

By Acuity

100%

0%

326 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sie 2026, 23:56 UTC

Correlated Moves
News

Royal Gold shares are higher in after-market trading following CEO Bill Heissenbuttel's upcoming presentation at the Jefferies Global Industrials Conference on September 10.

27 sie 2026, 23:56 UTC

Correlated Moves
News

Diamondback Energy has risen in after-market hours following its joint venture for the Solitude Pipeline System, with analysts estimating a fair value of $232.17.

27 sie 2026, 23:51 UTC

News

Carlyle Group reported second-quarter revenue exceeding analyst expectations. In after-market trading, shares are advancing, reflecting a solid performance backdrop.

27 sie 2026, 23:51 UTC

Correlated Moves
News

The USD/HUF is trading higher, reflecting gains since Wednesday. A decline in initial jobless claims suggests strength in the U.S. economy.

27 sie 2026, 23:31 UTC

News

NAPCO Security Technologies Inc shares are lower in after-market hours, following broader market declines despite a 10% revenue increase in the fiscal fourth quarter.

27 sie 2026, 23:26 UTC

News

Vanguard Mortgage-Backed Securities ETF is trading lower in after-market hours, amid a decline in the US 10Y Treasury Bond Index and investor sentiment shifts.

27 sie 2026, 23:11 UTC

News

Shares of Regenxbio are higher in after-market trading following a $949.4K insider purchase by director Gregor Ciongoli of 102.6K shares.

27 sie 2026, 23:06 UTC

Social Media
News

BioNTech SE's COVID-19 vaccine COMIRNATY® XFG receives FDA approval for adults 65 and older. Shares are trading higher in after-market hours.

27 sie 2026, 23:06 UTC

News

Shoals Technologies Group Inc shares declined in after-market trading despite winning a patent case against Voltage, LLC, with a jury awarding over $96 million.

27 sie 2026, 23:02 UTC

News

Permian Resources Corp shares are higher in after-market hours, boosted by Citigroup's outlook on the Permian Basin becoming the top U.S. natural gas producer.

27 sie 2026, 23:02 UTC

News

PDD Holdings reported second-quarter revenue of RMB112.4 billion, missing estimates. Shares are roughly flat in after-market trading amid rising operating expenses.

27 sie 2026, 23:02 UTC

Correlated Moves
News

Coinbase Global Inc. announced a token-backed mortgage product with Better Mortgage, boosting shares modestly higher in after-market trading.

27 sie 2026, 23:02 UTC

Social Media
News

Salesforce Inc. remains roughly flat in after-market hours amid discussions on short-selling dynamics and positive user experiences with its CRM system.

27 sie 2026, 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

27 sie 2026, 23:02 UTC

News

Main Street Capital plans a supplemental dividend for December 2026, continuing its $0.30-per-share quarterly distribution. Shares are trading higher in after-market hours.

27 sie 2026, 23:02 UTC

Social Media
News

CrowdStrike Holdings Inc shares are lower in after-market hours, reflecting broader market declines despite recent strong earnings and positive revenue outlook.

27 sie 2026, 23:02 UTC

News

SFL Corporation reported Q2 revenue of $200.77 million and net income of $33.79 million. Shares are higher in after-market trading following the announcement.

27 sie 2026, 23:02 UTC

Social Media
Event
News

Gap Inc. shares rise in after-market trading following Q2 earnings that beat EPS estimates and included an adjusted EPS guidance increase.

27 sie 2026, 23:02 UTC

Social Media
News

Ulta Beauty Inc. shares are lower in after-market trading despite reporting strong second-quarter earnings and raising fiscal year guidance for net sales growth.

27 sie 2026, 23:02 UTC

News

Constellation Brands names Alex Alvarez as chief supply chain officer for its beer division. Shares are higher in after-market trading following initial dips.

27 sie 2026, 23:02 UTC

News

Rivian Automotive shares fell in after-market trading after CFO Claire McDonough announced her departure for GE Vernova, effective October 30.

27 sie 2026, 23:02 UTC

Event
Social Media
News

Affirm Holdings shares rise in after-market hours following a record fiscal fourth-quarter profit and revenue of $1.17 billion, exceeding estimates.

27 sie 2026, 23:02 UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

27 sie 2026, 23:02 UTC

Social Media
News

Marvell Technology reported Q2 revenue of $2.74 billion, exceeding estimates, but shares are trading lower in after-market hours following the results.

27 sie 2026, 23:02 UTC

News
Correlated Moves

USD/PLN is gaining modestly today, influenced by initial jobless claims falling to 203,000, indicating ongoing strength in the labor market.

27 sie 2026, 23:02 UTC

Correlated Moves
Social Media
News

NVIDIA pauses revenue-sharing deals with AI cloud firms amid antitrust concerns, contributing to a modest decline in shares during after-market hours.

27 sie 2026, 23:02 UTC

Social Media
News

Veeva Systems Inc shares are lower in after-market trading, reflecting a broader market downturn despite earlier gains. The stock remains strong relative to its 20-day moving average.

27 sie 2026, 23:02 UTC

News

Bilibili Inc shares declined during after-market hours despite reporting strong growth in daily active users and advertising revenue. The stock remains below its 20-day moving average.

27 sie 2026, 23:01 UTC

News

Otis Worldwide Corp shares are lower in after-market trading, despite securing a significant contract for modernization at Tianjin 117 Tower in China.

27 sie 2026, 23:01 UTC

News
Correlated Moves

Intuit Inc. shares are lower in after-market trading following a downgrade by BofA Securities, which cut its fiscal 2027 revenue estimate to $23.4 billion.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

17.65% upside

12 Months Forecast

Average 14.53 USD  17.65%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat